XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 ...
Male contraceptive research is advancing, with oral, injectable, and topical options entering clinical trials. Both hormonal ...
The Council for the Indian School Certificate Examinations (CISCE) conducted the ISC Class 12 Economics Exam 2026 today, ...
Positive Phase 3 results of SCOUT-HCM trial highlight potential of Camzyos to be the first cardiac myosin inhibitor for the ...
WeRide Inc. ("WeRide” or the "Company”) (Nasdaq: WRD; HKEX: 0800), a global leader in autonomous driving technology, today announced its unaudited financial results for the fourth quarter and full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results